GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor (GLP-1R) agonist, delivered superior glycemic control and weight loss compared with GLP-1R agonism in patients with type 2 diabetes. However, the mechanism by which tirzepatide improves efficacy and how GIP receptor (GIPR) agonism contributes is not fully understood. Here, we show that tirzepatide is an effective insulin sensitizer, improving insulin sensitivity in obese mice to a greater extent than GLP-1R agonism. To determine whether GIPR agonism contributes, we compared the effect of tirzepatide in obese WT and Glp-1r-null mice. In the absence of GLP-1R-induced weight loss, tirzepatide improved insulin sensitivity by enhancing glucose disposal in white adipose tissue (WAT). In support of this, a long-acting GIPR agonist (LAGIPRA) was found to enhance insulin sensitivity by augmenting glucose disposal in WAT. Interestingly, the effect of tirzepatide and LAGIPRA on insulin sensitivity was associated with reduced branched-chain amino acids (BCAAs) and ketoacids in the circulation. Insulin sensitization was associated with upregulation of genes associated with the catabolism of glucose, lipid, and BCAAs in brown adipose tissue. Together, our studies show that tirzepatide improved insulin sensitivity in a weight-dependent and -independent manner. These results highlight how GIPR agonism contributes to the therapeutic profile of dual-receptor agonism, offering mechanistic insights into the clinical efficacy of tirzepatide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, binding to the GLP-1 receptor also seems significant in tirzepatide’s cell surface receptor mechanism, as tirzepatide had no effect on body weight, food intake, fasting insulin levels, skeletal muscle, subcutaneous adipose tissue endogenous glucose production, or insulin-stimulated glucose uptake in GLP-1 receptor non-expressing knockout mice [93].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In preclinical studies, tirzepatide improved insulin sensitivity in GLP-1 receptor null mice, thus demonstrating the important role of GIP receptor agonism in insulin sensitization [9] in addition to contributions of both GLP-1 and GIP receptor agonism to glucose-dependent insulin secretion [10].”
From Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1). (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postprandial excursions of insulin drive glucose dis posal through actions in muscle and adipose tissue, along with effects of postprandial excursions in GIP, to enhance insulin sensitivity and augment glucose disposal in adipose tissue (2-5).”
From Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In GlP-1 R-null mice, tirzepatide improved insulin sensitivity by enhancing glucose disposal in white adipose tissue in the absence of GLP-1 RA-induced weight loss.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [169]
The cited source says what the claim attributes to it.
In the citing paper
“Murine studies indicate that GIP-dependent insulin sensitization of adipose tissue may be another major GIP action [122].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [122]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 17×
“Thus, while it is likely to make a smaller contribution in humans (compared with mice), our data suggest that BAT may aid weight-dependent mechanisms in the lowering of circulating lipids and BCAAs, enhancing the improvement of insulin sensitivity by tirzepatide in patients with T2DM (44, 52).”
BackgroundInfluentialIdentification and Importance of Brown Adipose Tissue in Adult Humans
Cypess, A. M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A. B., Kuo, F. C., Palmer, E. L., Tseng, Y.-H., Doria, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810780 · Cited by 4,399
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · cited 1×
“Although the cause of obesity-associated IR is intensely debated (4, 66, 67), recently, a strong association between elevated BCAAs/BCKAs, obesity, systemic IR, and T2DM has consistently been reported (66, 68).”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Unexpected evidence for active brown adipose tissue in adult humans
Nedergaard, J., Bengtsson, T., & Cannon, B. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00691.2006 · Cited by 1,824 · cited 1×
“Therefore, while BAT has classically been considered to have a limited effect on human metabolism (72, 73), studies show that adult humans have functional BAT (74), which when activated, is capable of positively affecting systemic metabolism (43, 75, 76).”
BackgroundBrown adipose tissue activity controls triglyceride clearance
Bartelt, A., Bruns, O. T., Reimer, R., Hohenberg, H., Ittrich, H., Peldschus, K., Kaul, M. G., Tromsdorf, U. I., Weller, H., Waurisch, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2297 · Cited by 1,608
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 1×
“The glycemic benefits associated with GLP-1RAs are due to enhanced β cell function, delayed gastric emptying, and weight loss–driven improvements in insulin sensitivity (9).”
Background
Cited by
Items 101–200 of 256
Razzaki, T. S., Weiner, A., & Shukla, A. P. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s328056 · Cited by 16
Kushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023) · Clinical Diabetes · doi:10.2337/cd22-0029 · Cited by 14
GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
Furber, E. C., Hyatt, K., Collins, K. A. L., Yu, X., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., O’Farrell, L. S., et al. (2023) · Diabetes · doi:10.2337/db23-0172 · Cited by 17
Self-citationPeters, A. L., Buzzetti, R., Lee, C. J., Pavo, I. J., Liu, M., Karanikas, C. A., & Paik, J. S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae372 · Cited by 18
Tirzepatide: a novel therapeutic approach for Alzheimer’s disease
Alshehri, G. H., Al-Kuraishy, H. M., Waheed, H. J., Al-Gareeb, A. I., Faheem, S. A., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01649-z · Cited by 21
Petersen, J., Merrild, C., Lund, J., Holm, S., & Clemmensen, C. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102027 · Cited by 13
Reitz, J., Rosoff, D. B., Perlstein, T., Wagner, A., Jung, J., Wagner, J., Reiner, B. C., & Lohoff, F. W. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03199-3 · Cited by 18
Roell, W. C., Alsina‐Fernandez, J., Qu, H., Coşkun, T., Benson, C., Haupt, A., Kelly, R. P., O’Farrell, L. S., Sloop, K. W., Steele, J. P., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102298 · Cited by 13
Self-citationSawamura, T., Mizoguchi, R., Ohmori, A., Kometani, M., Yoneda, T., & Karashima, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01472-w · Cited by 18
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Self-citationClass B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease
Sangwung, P., Ho, J. D., Siddall, T., Lin, J., Tomás, A., Jones, B. J., & Sloop, K. W. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00371.2023 · Cited by 15
Self-citationFeetham, C. H., Ai, M., Culotta, I., Costa, A., Hunter, J., Brown, R. A., Coşkun, T., Emmerson, P. J., D’Agostino, G., & Luckman, S. M. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102214 · Cited by 13
Chen, M., Zhao, N., Shi, W., Xing, Y., Liu, S., Meng, X., Li, L., Zhang, H., Meng, Y., Xie, S., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf005 · Cited by 17
Add-on value of tirzepatide versus semaglutide
Scheen, A. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00116-4 · Cited by 14
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Boer, G. A., Hunt, J. E., Gabe, M. B. N., Windeløv, J. A., Sparre‐Ulrich, A. H., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15894 · Cited by 13
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Yammine, L., Picatoste, B., Abdullah, N., Leahey, R. A., Johnson, E. F., Gómez-Banoy, N., Rosselot, C., Wen, J., Hossain, T., Goncalves, M. D., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101831 · Cited by 10
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Self-citationInsights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
Wang, S., Liu, Y., Yan, Z., Huang, X., Liao, Y., Tang, C., Jing, L., Zhou, Z., Han, J. D. J., Tang, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02032 · Cited by 10
Do anti-obesity medical treatments have a direct effect on adipose tissue?
Vergès, B. L. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.05.021 · Cited by 10
Tirzepatide a novel anti diabetic molecule unfold dual action
Sweta, Gupta, S., Bansal, S., Devi, S., Sharma, S., Laxmi, L., & Deepa (2024) · Discover Public Health · doi:10.1186/s12982-024-00200-2 · Cited by 14
Hegab, I. I., El‐Horany, H. E., Abd‐Ellatif, R. N., Nasef, N. A., okasha, A. H., Emam, M. N., Hassan, S., Elseady, W. S., Radwan, D. A., El‐Esawy, R. O., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010001 · Cited by 15
The evolution of the therapeutic concept ‘GIP receptor antagonism’
Koefoed-Hansen, F., Helsted, M. M., Kizilkaya, H. S., Lund, A., ROSENKILDE, M. M., & Gasbjerg, L. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1570603 · Cited by 9
SNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · Diabetes Care · doi:10.2337/dci25-0015 · Cited by 19
Is polypharmacy the future for pharmacological management of obesity?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100322 · Cited by 12
Davies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
Willency, J. A., Lin, Y., & Pirro, V. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.102884 · Cited by 9
Self-citationThe unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Alluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Ma, T., Song, F., Pan, Y., He, Y., Cao, X., Zhang, Y., Song, G., & Ren, L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1659233 · Cited by 10
Marcondes‐de‐Castro, I. A., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103146 · Cited by 9
Lyons, S. A., Lea, M. B. S., Parikh, M., Guo, Z., Kagdi, S., Bisnauth, A. R., Pitino, J. R., Ziai, S., Mir, N., Tyrrell, A. D., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00582-7 · Cited by 9
Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease
Ma, J., Tao, M., Zhang, W., Zhou, L., Zhang, H., Li, F., Zhang, H., Yao, D., Lu, W., & Wang, M. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1715024 · Cited by 13
Pacini, G., & Åhrén, B. (2023) · Peptides · doi:10.1016/j.peptides.2023.171117 · Cited by 8
An insoluble cellulose nanofiber with robust expansion capacity protects against obesity
Yu, J. G., Gao, M., Wang, L., Guo, X., Liu, X., Sheng, M., Cheng, S., Guo, Y., Wang, J., Zhao, C., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134401 · Cited by 9
Hamamoto, Y., Oura, T., & Hirase, T. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01704-z · Cited by 10
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 10
GLP-1 analogues in clinical management of obesity
Agius, R., Matta-Coelho, C., & McGowan, B. M. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100360 · Cited by 9
Tirzepatide as an Insulin Sensitizer
Ferrannini, E. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab803 · Cited by 7
Alcaino, C., Reimann, F., & Gribble, F. M. (2024) · The Journal of Physiology · doi:10.1113/jp286293 · Cited by 10
Mimura, H., Oura, T., Chin, R., Takeuchi, M., Fujihara, K., & Sone, H. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14395 · Cited by 8
Yamaguchi, Y., Kuwata, H., Imura, M., Moyama, S., Usui, R., Matsushiro, M., Hamamoto, Y., Yamada, Y., Seino, Y., & Yamazaki, Y. (2025) · Diabetologia · doi:10.1007/s00125-025-06493-5 · Cited by 6
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
Alavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
Müller, T. D., & Blüher, M. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01530-0 · Cited by 11
The GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · doi:10.2337/figshare.19184462 · Cited by 6
Rangraze, I. R., Patoulias, D., Karakasis, P., El‐Tanani, M., & Rizzo, M. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2408753 · Cited by 8
Marinho, T. D. S., Bittencourt, J. D. O. A., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150113 · Cited by 9
Mestres‐Arenas, A., Quesada‐López, T., Blasco‐Roset, A., Giralt, M., Villarroya, F., Planavila, A., & Peyrou, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119057 · Cited by 8
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Jiménez-Martí, E., Hurtado-Genovés, G., Aguilar-Ballester, M., Martínez‐Hervás, S., & Navarro, H. G. (2022) · Nutrients · doi:10.3390/nu14183775 · Cited by 7
Tirzepatide inhibits tumor growth in mice with diet-induced obesityPreprint
Huang, L., Zeng, J., Wang, Y., & Pollak, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.22.546093 · Cited by 6
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Zheng, Z., Pettus, J., Warner, A., Jones, B., Pugsley, M., Stege, J. T., Hirakawa, B. P., Jaiman, M., Tolentino, J. C., Lee, T., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102340 · Cited by 4
Dan, K., Sanada, J., Kimura, T., Iwamoto, Y., Sugisaki, T., Iwamoto, H., Fushimi, Y., Nogami, Y., Shirakiya, Y., Shimoda, M., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-42437-8 · Cited by 5
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
Reis‐Barbosa, P. H., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15937 · Cited by 6
Jaso-Vera, M. E., Takaoka, S., Patel, I., & Ruan, X. (2024) · Human Genetics · doi:10.1007/s00439-024-02654-5 · Cited by 4
Self-citationManchanda, Y., Jones, B. J., Carrat, G., Ramchunder, Z., Marchetti, P., Leclerc, I., Thennati, R., BURADE, V. S., Natarajan, M., Shahi, P. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16652 · Cited by 5
A Gut-Centric Model of Metabolic Homeostasis
Rajagopalan, H., López-Talavera, J. C., Klonoff, D. C., & Cherrington, A. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211044523 · Cited by 5
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice
Davies, I., Turland, A., Tran, H. D., Wong, C., Cahn, O., Dunsterville, C., Sun, Y., Xiao, Y., Murphy, K. G., Bloom, S. R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70300 · Cited by 3
Bittencourt, J. D. O. A., Marcondes‐de‐Castro, I. A., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124155 · Cited by 3
Ono, Y. O. I., Shinohara, K., Nakashima, H., Miyamoto, R., Hara, A., Ikeda, S., Matsumoto, S., Yoshida, D., Nakashima, R., Matsushima, S., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02632-6 · Cited by 3
Bauri, R., Bele, S. D., Edelli, J., Reddy, N. C., Kurukuti, S., Devasia, T., Ibrahim, A., Rai, V., & Mitra, P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2023 · Cited by 4
Dsouza, P. D., Chitralu, S. P. P., Khan, R., & Nyamagoud, S. B. (2025) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_386_24 · Cited by 3
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
Tirzepatide – a new analogue of incretin hormones
Anglart, G., Janik, L., & Dettlaff, K. (2023) · Farmacja Polska · doi:10.32383/farmpol/174068 · Cited by 4
Xie, S., Chen, D., Cai, Y., Xu, L., Liao, O., Jia, X., Ji, X., Chen, H., Mao, J., & Cai, J. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.022 · Cited by 3
Marcondes‐de‐Castro, I. A., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002683 · Cited by 4
Santana-Oliveira, D. A., Souza-Tavares, H., Fernandes‐da‐Silva, A., Marinho, T. D. S., Silva-Veiga, F. M., Daleprane, J. B., & Souza‐Mello, V. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112533 · Cited by 2
Windram, M., Lovelock, D. F., Carew, J. M., Krieman, C. G., Hendershot, C. S., & Besheer, J. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06854-3 · Cited by 8
Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain
Kim, H., Kim, S. W., Choi, C., Joo, S., Kim, G., Kim, M., Yang, E., Lee, J., Chung, S., Jeong, L. S., et al. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01575-9 · Cited by 3
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., D’Alessio, D. A., & Campbell, J. E. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.12.002 · Cited by 3
Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study
Guo, M., Chen, S., Dong, H., Cai, M., Guo, M., & Cheng, H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05113-2 · Cited by 2
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
GLP-1/GIP Receptor Agonists: Mechanism of Action of Tirzepatide
Oh, T. J. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.2.76 · Cited by 2
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 4
Tirzepatide differentially affects body weight in mice and humans
Novikoff, A., & Müller, T. D. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01139-3 · Cited by 3
Mi, L., Li, T., Xiang, X., Zhou, Y., Xiong, N., Chen, Y., Chen, J., Shang, S., Chen, S., Cheung, W. W., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.009 · Cited by 2
Effet du bi-agoniste GLP-1/GIP sur le poids, le tissu adipeux et les lipides
Vergès, B. L. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.06.004 · Cited by 3
Zenimaru, Y., & Harada, N. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14305 · Cited by 1
Biased Agonism in Incretin-based Therapies
Seshadri, K. (2025) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071251336542 · Cited by 1
Corbalan, J. J., Petronella, B. A., Huang, C., Beasley, J. R., Merritt, J. R., Mugrage, B., & Nickels, J. T. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152360 · Cited by 1
Reis‐Barbosa, P. H., Cardoso, L. E. M., & Mandarim‐de‐Lacerda, C. A. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152913 · Cited by 1
Zhang, F., Chen, W., Wang, H., Wu, D., Chen, Z., Cheng, R., Hu, J., Xie, L., Qiu, Y., Zhou, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.006 · Cited by 3
Song, S., Hyeon, M., Kim, S., Kang, Y., Hahm, S., Park, E. W., Shin, B. S., & Shin, S. (2026) · Journal of Analytical Science & Technology · doi:10.1186/s40543-026-00540-5 · Cited by 1
Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity
Dong, S., Xu, Y., Gan, R., Zhang, A., He, J., & Tang, Q. (2026) · Medicinal Research Reviews · doi:10.1002/med.70049 · Cited by 1
Corbalan, J. J., Jagadeesan, P., Huang, C., Beasley, J. R., & Nickels, J. T. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70131 · Cited by 1
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 3
Eisa, N., & Barood, O. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.04.014 · Cited by 3
Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists
Lixi, F., Troisi, M., Calabresi, V., Giagoni, A., Rossi, C., Timofte-Zorila, M.-M., Tarași, T.-C., Vitiello, L., Tomi, M.-I., Gheorghe, A. G., et al. (2026) · Vision · doi:10.3390/vision10020029 · Cited by 3
Metadata
- Authors
- Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., Furber, E. P. S. C., Ruan, X., O’Farrell, L. S., Long, A. M., Dogra, M., Willency, J. A., Lin, Y., Ding, L., Cheng, C. C., Cabrera, O., Briere, D. A., Alsina-Fernandez, J., Gimeno, R. E., Moyers, J. S., Coskun, T., Coghlan, M. P., Sloop, K. W., & Roell, W. C.
- Affiliations
- Eli Lilly (United States) (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2021-06-15
- Volume
- 131
- Issue
- 12
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC8203452
- OpenAlex
- W3161292733
- Cited by
- 256
- References
- 82
- Citations by year
- 2026: 58 · 2025: 66 · 2024: 54 · 2023: 34 · 2022: 34 · 2021: 10
- FWCI
- 24.64
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- tirzepatide, GLP-1 receptor agonism, insulin sensitization, obesity, type 2 diabetes, glucose disposal, white adipose tissue, brown adipose tissue, branched-chain amino acids, keto acids
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Amino Acids, Branched-Chain, Animals, Body Weight, Gastric Inhibitory Polypeptide, Insulin Resistance, Obesity, Mice, Knockout, Mice, Adipose Tissue, White
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.